VALNEVA SE (AYJ.DE) Stock Fundamental Analysis
Europe - FRA:AYJ - FR0004056851 - Common Stock
4.1 EUR
+0.12 (+2.91%)
Overall AYJ gets a fundamental rating of 2 out of 10. We evaluated AYJ against 76 industry peers in the Biotechnology industry. Both the profitability and financial health of AYJ have multiple concerns. AYJ is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AYJ has reported negative net income.
In the past year AYJ has reported a negative cash flow from operations.
AYJ had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: AYJ reported negative operating cash flow in multiple years.
1.2 Ratios
AYJ has a Return On Assets (-18.09%) which is comparable to the rest of the industry.
AYJ's Return On Equity of -45.87% is in line compared to the rest of the industry. AYJ outperforms 58.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROIC | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AYJ's Gross Margin of 48.94% is in line compared to the rest of the industry. AYJ outperforms 51.35% of its industry peers.
AYJ's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AYJ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
2. Health
2.1 Basic Checks
AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
AYJ has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AYJ has been increased compared to 5 years ago.
The debt/assets ratio for AYJ has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.21, we must say that AYJ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.21, AYJ is in line with its industry, outperforming 48.65% of the companies in the same industry.
A Debt/Equity ratio of 0.80 indicates that AYJ is somewhat dependend on debt financing.
AYJ has a Debt to Equity ratio (0.80) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.21 |
ROIC/WACCN/A
WACC7.74%
2.3 Liquidity
A Current Ratio of 2.27 indicates that AYJ has no problem at all paying its short term obligations.
The Current ratio of AYJ (2.27) is comparable to the rest of the industry.
AYJ has a Quick Ratio of 1.77. This is a normal value and indicates that AYJ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.77, AYJ perfoms like the industry average, outperforming 47.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
AYJ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.65%.
AYJ shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.49%.
The Revenue has been growing slightly by 6.09% on average over the past years.
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
3.2 Future
The Earnings Per Share is expected to grow by 53.87% on average over the next years. This is a very strong growth
Based on estimates for the next years, AYJ will show a quite strong growth in Revenue. The Revenue will grow by 17.97% on average per year.
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AYJ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AYJ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AYJ's earnings are expected to grow with 120.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
5. Dividend
5.1 Amount
No dividends for AYJ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:AYJ (10/31/2025, 7:00:00 PM)
4.1
+0.12 (+2.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.62%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap352.05M
Revenue(TTM)291.38M
Net Income(TTM)-85509000
Analysts84
Price Target7.11 (73.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.02%
PT rev (3m)-1.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.9%
EPS NY rev (1m)0%
EPS NY rev (3m)2.41%
Revenue NQ rev (1m)-7.89%
Revenue NQ rev (3m)-11.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.89 | ||
| P/tB | 2.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS3.39
BVpS2.17
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% | ||
| FCFM | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 71.71% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | -0.21 |
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-280.12%
EBIT Next 3Y59.13%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A
VALNEVA SE / AYJ.DE FAQ
What is the fundamental rating for AYJ stock?
ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE.
What is the valuation status for AYJ stock?
ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (AYJ.DE). This can be considered as Overvalued.
How profitable is VALNEVA SE (AYJ.DE) stock?
VALNEVA SE (AYJ.DE) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for AYJ stock?
The Earnings per Share (EPS) of VALNEVA SE (AYJ.DE) is expected to decline by -580.55% in the next year.